GEFINITIB (ZD 1839) BASED THERAPY IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Papi, M. [1 ]
Genestreti, G. [1 ]
Tassinari, D. [1 ]
Pasquini, E. [1 ]
Nicolini, M. [1 ]
Fabbri, P. [1 ]
Poggi, B. [1 ]
Fantini, M. [1 ]
Tamburini, E. [1 ]
Oliverio, G. [1 ]
Rudnas, B. [1 ]
Ravaioli, A. [1 ]
机构：
[1] City Hosp, Dept Oncol, Rimini, Italy
来源：
ANNALS OF ONCOLOGY | 2004年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：33 / 33
页数：1
相关论文
共 50 条
  • [1] Gefitinib (ZD1839) as compassionate use therapy in patients (pts) with advanced non-small-cell lung cancer (NSCLC) after failing prior chemotherapy
    Genestreti, G.
    Giovannini, M.
    Fiorio, E.
    Colaluca, P.
    Cipriani, A.
    Palazzi, M.
    Salmaso, F.
    Cartei, G.
    Cetto, G. L.
    Santo, A.
    ANNALS OF ONCOLOGY, 2005, 16 : 26 - 27
  • [2] ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC):: report of four cases
    Cappuzzo, F
    Calandri, C
    Bartolini, S
    Crinò, L
    BRITISH JOURNAL OF CANCER, 2003, 89 (02) : 246 - 247
  • [3] Gefitinib ('Iressa', ZD1839) in advanced non-small-cell lung cancer patients progressed to chemotherapy
    Cortes-Funes, H
    Figueiras, MC
    Martín-Algarra, S
    Salinas, P
    Massutí, B
    Gascón, P
    Rosell, R
    BRITISH JOURNAL OF CANCER, 2003, 89 : S27 - S27
  • [4] ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases
    F Cappuzzo
    C Calandri
    S Bartolini
    L Crinò
    British Journal of Cancer, 2003, 89 : 246 - 247
  • [5] Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer
    Hotta, K
    Kiura, K
    Ueoka, H
    Tabata, M
    Fujiwara, K
    Kozuki, T
    Okada, T
    Hisamoto, A
    Tanimoto, M
    LUNG CANCER, 2004, 46 (02) : 255 - 261
  • [6] Combination therapy with gefitinib (ZD1839) and rofecoxib in platinum-pretreated relapsed non-small-cell lung cancer (NSCLC).
    O'Byrne, K
    Clarke, L
    Dunlop, D
    Ranson, M
    Danson, S
    Botwood, N
    Carbone, D
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 641S - 641S
  • [7] GEFITINIB (ZD1839-'IRESSA') AS SALVAGE THERAPY IN PRETREATED PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC). FINAL DATA FROM A COMPASSIONATE USE PROGRAM
    Ferrara, Carmine
    Guerriero, Ciro
    Barzelloni, Maria Luisa
    Colantuoni, Giuseppe
    Maione, Paolo
    Rossi, Antonio
    Gridelli, Cesare
    ANNALS OF ONCOLOGY, 2004, 15 : 28 - 28
  • [8] Third-line treatment with ZD 1839 (IRESSA) in patients with advanced non-small-cell lung cancer - Preliminary results
    Amaducci, L
    Longo, L
    Tamberi, S
    Gambi, A
    TUMORI, 2003, : S66 - S66
  • [9] Pemetrexed in maintenance therapy of 164 patients with advanced non-small-cell lung cancer (NSCLC)
    Skrickova, Jana
    Bortlicek, Zbynek
    Hejduk, Karel
    Pesek, Milos
    Kolek, Vitezslav
    Tomiskova, Marcela
    Grygarkova, Ivona
    Koubkova, Leona
    Cernovska, Marketa
    Roubec, Jaromir
    Salajka, Frantisek
    Zemanova, Milada
    Coupkova, Helena
    Satankova, Monika
    Marel, Milosalav
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [10] Gefitinib ('Iressa', ZD1839) as treatment for non-small-cell lung cancer
    Razis, E
    Papadopoulos, S
    Skarlos, D
    Exarchakos, M
    Christodoulou, C
    Karina, M
    Xylouri, M
    Labropoulos, S
    BRITISH JOURNAL OF CANCER, 2003, 89 : S32 - S32
12345